Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population

Kimbach Tran Carpiuc1, Gianantonio Rosti, Fausto Castagnetti

  • 1Pharmerit North America LLC, Bethesda, MD, USA.

Oncotargets and Therapy
|December 3, 2010
PubMed